BCL2L1 and Thrombocytopenia: After an initial positive assessment on multiple cellular lines, where ABT-263 reported stronger inhibitory actions, presumably by targeting both BCL-xL and BCL-2, advanced clinical studies unfortunately revealed major physiological pitfalls such as thrombocytopenia (Vandenberg and Cory, 2013).